Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$28.70 -0.3%	$27.69	$17.82 ▼ $30.69	$2.09B	0.05	699,427 shs	24,591 shs
NXTC NextCure	$0.47 +4.2%	$0.47	$0.22 ▼ $1.82	$13.16M	1.06	170,540 shs	57,672 shs
PAHC Phibro Animal Health	$31.68 +0.9%	$24.06	$16.16 ▼ $31.60	$1.28B	0.75	255,047 shs	34,064 shs
PHAT Phathom Pharmaceuticals	$9.28 -1.0%	$6.53	$2.21 ▼ $19.71	$647.87M	0.45	1.93 million shs	65,590 shs
SUPN Supernus Pharmaceuticals	$32.73 +0.2%	$32.24	$27.05 ▼ $40.28	$1.83B	0.7	561,462 shs	25,846 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	+5.84%	+4.96%	-5.04%	+54.42%	+42.36%
NXTC NextCure	-1.23%	+5.07%	-14.85%	+66.67%	-71.88%
PAHC Phibro Animal Health	+4.22%	+12.35%	+29.55%	+77.14%	+83.14%
PHAT Phathom Pharmaceuticals	+3.88%	+5.16%	+6.12%	+127.98%	-10.85%
SUPN Supernus Pharmaceuticals	+1.81%	+1.87%	-1.80%	+5.15%	+22.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KNSA Kiniksa Pharmaceuticals International	3.4478 of 5 stars	3.5	4.0	0.0	0.0	2.1	3.3	0.6
NXTC NextCure	4.1958 of 5 stars	3.5	3.0	0.0	4.3	0.6	1.7	1.3
PAHC Phibro Animal Health	3.6956 of 5 stars	0.9	2.0	2.5	1.1	3.0	3.3	2.5
PHAT Phathom Pharmaceuticals	3.3323 of 5 stars	4.5	1.0	0.0	0.0	0.0	5.0	0.6
SUPN Supernus Pharmaceuticals	2.8297 of 5 stars	2.2	2.0	0.0	4.1	3.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	37.05% Upside
NXTC NextCure	2.67	Moderate Buy	$3.50	646.27% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-22.98% Downside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	88.58% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	10.01% Upside

Current Analyst Ratings Breakdown

Latest NXTC, PHAT, SUPN, KNSA, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.95	N/A	N/A	$6.60 per share	4.35
NXTC NextCure	N/A	N/A	N/A	N/A	$2.34 per share	N/A
PAHC Phibro Animal Health	$1.02B	1.26	$2.22 per share	14.25	$6.34 per share	5.00
PHAT Phathom Pharmaceuticals	$81.86M	7.91	N/A	N/A	($3.71) per share	-2.50
SUPN Supernus Pharmaceuticals	$661.82M	2.77	$4.26 per share	7.69	$18.76 per share	1.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	114.80	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
NXTC NextCure	-$55.65M	-$1.76	N/A	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	40.62	15.09	0.50	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	29.48	22.73	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)

Latest NXTC, PHAT, SUPN, KNSA, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NXTC NextCure	-$0.39	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SUPN Supernus Pharmaceuticals	$0.47	N/A	N/A	N/A	$154.06 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/1/2025	Q1 2025	NXTC NextCure	-$0.40	-$0.39	+$0.01	-$0.39	N/A	N/A
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.52%	N/A	61.54%	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest NXTC, PHAT, SUPN, KNSA, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
NXTC NextCure	N/A	10.26	10.26
PAHC Phibro Animal Health	2.67	2.91	1.23
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KNSA Kiniksa Pharmaceuticals International	53.95%
NXTC NextCure	42.65%
PAHC Phibro Animal Health	99.34%
PHAT Phathom Pharmaceuticals	99.01%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
KNSA Kiniksa Pharmaceuticals International	53.48%
NXTC NextCure	17.90%
PAHC Phibro Animal Health	50.07%
PHAT Phathom Pharmaceuticals	23.00%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
NXTC NextCure	90	28.05 million	23.03 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable

NXTC, PHAT, SUPN, KNSA, and PAHC Headlines

Recent News About These Companies

2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution

1 hour ago | finance.yahoo.com

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 9 at 5:15 AM | msn.com

Head-To-Head Analysis: Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL)

July 5, 2025 | americanbankingnews.com

Meritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

July 4, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (SUPN) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.

July 3, 2025 | marketbeat.com

Sage Sacks Entire Staff After Supernus Buyout

June 30, 2025 | biospace.comB

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

June 27, 2025 | msn.com

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

June 23, 2025 | uk.finance.yahoo.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Supernus Pharma to Buy Sage Therapeutics for Up to $795 Million

June 16, 2025 | marketwatch.com

Supernus enters depression drug market with up to $795 million Sage deal

June 16, 2025 | msn.com

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

June 16, 2025 | msn.com

Supernus to acquire depression drugmaker Sage

June 16, 2025 | msn.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

June 16, 2025 | prnewswire.com

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal

June 16, 2025 | gurufocus.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...

June 16, 2025 | gurufocus.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock news

June 16, 2025 | gurufocus.com

Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.

June 16, 2025 | barrons.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...

June 16, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, PHAT, SUPN, KNSA, and PAHC Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.70 -0.10 (-0.35%)

As of 10:25 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

NextCure NASDAQ:NXTC

$0.47 +0.02 (+4.22%)

As of 10:22 AM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Phibro Animal Health NASDAQ:PAHC

$31.68 +0.29 (+0.92%)

As of 10:26 AM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.28 -0.09 (-0.96%)

As of 10:25 AM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Supernus Pharmaceuticals NASDAQ:SUPN

$32.72 +0.06 (+0.17%)

As of 10:25 AM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time